Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%

Written by Peter A. McCullough, MD, MPH

Rare illnesses which are mild should not be the target for mass vaccination. Because so few people get the problem, and in the case of respiratory syncytial virus, the illness is so mild and easily treatable with albuterol and budesonide nebulizers, it is hard to make the case for mass vaccination with a novel mRNA platform.

Continue Reading 1 Comment